ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2024 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 4.380-4.820 for the period, compared to the consensus estimate of 4.490. The company issued revenue guidance of $540.0 million-$560.0 million, compared to the consensus revenue estimate of $554.6 million. ANI Pharmaceuticals also updated its FY24 guidance to $4.38-4.82 EPS.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Guggenheim reissued a buy rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. HC Wainwright reissued a buy rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of Buy and an average target price of $82.75.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $57.00 on Wednesday. The stock has a 50 day moving average price of $63.12 and a 200-day moving average price of $63.29. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of 39.56 and a beta of 0.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.12 and a current ratio of 3.95.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the previous year, the business posted $1.06 earnings per share. The business’s revenue was up 18.5% compared to the same quarter last year. Equities analysts expect that ANI Pharmaceuticals will post 3.3 EPS for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $64.41, for a total value of $1,288,200.00. Following the completion of the sale, the senior vice president now owns 213,226 shares of the company’s stock, valued at $13,733,886.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $64.41, for a total value of $1,288,200.00. Following the sale, the senior vice president now owns 213,226 shares in the company, valued at $13,733,886.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Ori Gutwerg sold 2,985 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $67.00, for a total value of $199,995.00. Following the sale, the senior vice president now owns 77,227 shares of the company’s stock, valued at $5,174,209. The disclosure for this sale can be found here. Insiders have sold 148,202 shares of company stock valued at $9,387,374 in the last ninety days. 12.70% of the stock is owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.